• Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing its bispecific T cell engagers CLN-978 and velinotamig produced strong clinical responses and favorable safety in heavily pre-treated rheumatoid arthritis and systemic lupus erythematosus patients, including remissions and complete renal responses in lupus nephritis.
• By positioning T cell engagers as off-the-shelf “immune reset” therapies across multiple autoimmune conditions, Cullinan is expanding its oncology-derived platform into a broader chronic disease opportunity set.
• We’ll now examine how this push into immune-resetting T cell engagers for refractory autoimmune disease could reshape Cullinan’s investment narrative.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

What Is Cullinan Therapeutics' Investment Narrative?

To own Cullinan Therapeutics, you really have to believe that its oncology-born T cell engager platform can carve out a meaningful role in hard‑to‑treat autoimmune disease while it continues to invest heavily with no commercial revenue. The June 2026 CLN‑978 and velinotamig data strengthen the near‑term catalyst stack, adding more weight to upcoming RA and SLE readouts in the second half of 2026 and the planned 2027 trial starts, and they help explain why the share price has already moved sharply off its lows and closer to consensus fair value. At the same time, the story is still early: Cullinan is loss‑making, burning roughly US$50 million a quarter, reliant on fresh capital after filing a US$200 million ATM, and concentrated in a few core assets that could materially affect the equity if later‑stage data disappoint.

However, investors should also weigh how Cullinan’s cash burn and trial outcomes could affect future dilution. Our expertly prepared valuation report on Cullinan Therapeutics implies its share price may be too high.

Exploring Other Perspectives

The Simply Wall St Community currently has 1 fair value estimate clustered around US$31.55 per share, while recent data shifts both the potential upside and the clinical and funding risks that could drive very different views among other investors.

Explore another fair value estimate on Cullinan Therapeutics - why the stock might be worth as much as 78% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cullinan Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Cullinan Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cullinan Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.